[HTML][HTML] A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
T Kimura, JM Leal, A Simpson, NL Warner, BJ Berube… - Molecular Therapy, 2023 - cell.com
RNA vaccines possess significant clinical promise in counteracting human diseases caused
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
T Kimura, JM Leal, A Simpson… - … therapy: the journal …, 2023 - pubmed.ncbi.nlm.nih.gov
RNA vaccines possess significant clinical promise in counteracting human diseases caused
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation.
T Kimura, JM Leal, A Simpson, NL Warner… - … Therapy: the Journal …, 2023 - europepmc.org
RNA vaccines possess significant clinical promise in counteracting human diseases caused
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
[HTML][HTML] A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
T Kimura, JM Leal, A Simpson, NL Warner, BJ Berube… - Molecular Therapy, 2023 - Elsevier
RNA vaccines possess significant clinical promise in counteracting human diseases caused
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …
by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought …